Pre-progression(N = 7332) | Post-progression(N = 5062) | Total(N = 8862) | |
---|---|---|---|
Gender | |||
Men | 3894 (53.1%) | 2829 (55.9%) | 4764 (53.8%) |
Women | 3438 (46.9%) | 2233 (44.1%) | 4098 (46.2%) |
Age (years) | |||
Mean ± SD | 63.4 ± 15.9 | 64.2 ± 15.7 | 63.7 ± 15.9 |
Median (Min. – Max.) | 65 (18–103) | 66 (18–99) | 65 (18–103) |
Initial progression marker | |||
Cerebral metastasesa | 1348 (26.6%) | ||
New metastases in other sites | 2027 (40.0%) | ||
Palliative care | 1058 (20.9%) | ||
With cerebral metastases | 300 (5.9%) | ||
Without cerebral metastases | 758 (15.0%) | ||
Treatment change | 629 (12.4%) |